Compare AMRX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRX | RLAY |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 2018 | 2020 |
| Metric | AMRX | RLAY |
|---|---|---|
| Price | $17.01 | $20.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $15.60 | ★ $19.50 |
| AVG Volume (30 Days) | 2.2M | ★ 4.2M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.89 | 31.78 |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $4.48 | N/A |
| Revenue Next Year | $7.13 | $324.03 |
| P/E Ratio | $89.53 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $7.67 | $3.03 |
| 52 Week High | $17.86 | $20.79 |
| Indicator | AMRX | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 68.98 | 67.09 |
| Support Level | $12.46 | $12.10 |
| Resistance Level | $17.86 | N/A |
| Average True Range (ATR) | 0.54 | 1.31 |
| MACD | -0.13 | 0.17 |
| Stochastic Oscillator | 54.92 | 85.38 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.